On May 28, join Life Science Tennessee members from across the state for a virtual happy hour to stay connected and learn about the latest research and innovations. During this session, we will dig deeper into COVID-19 testing, treatment and prevention with leading experts on vaccine development and rapid, point-of-contact testing.
Featured speakers include (full bios below):
- Dr. Rob Carnahan, Associate Director of the Vanderbilt Vaccine Center
- Dr. Jonathan Peat, Business Development Manager of QuantuMDx
- Dr. Andrea J. Pruijssers, Research Assistant Professor of Pediatrics at the Vanderbilt Institute for Infection, Immunology and Inflammation
Note: We will share a Zoom link with all registrants prior to the happy hour. Register here!
Learn more about the speakers
Dr. Rob Carnahan is the Associate Director of the Vanderbilt Vaccine Center. After several years working for Eli Lilly in the US and in Strasbourg, France, he returned to academics as a visiting researcher at the Institut Pasteur in Paris, France. He subsequently returned to the US to complete his Ph.D. in Cell Biology at Vanderbilt University. In 2006, he was appointed as Director of the Vanderbilt Antibody and Protein Resource (VAPR). During his time leading this institutional shared resource lab, he has guided a technology expansion from being a lab one focused exclusively on generating monoclonal antibodies, to one that now has expertise in wide array of molecular approaches, including antibody and recombinant protein engineering, diagnostic and assay development, and biologics cell line development. In 2010 he co-founded the Antibody-Technologies Research Group. This international group, part of a larger scientific organization (Association of Biomolecular Resource Facilities), collaborates to develop technical standards, advances in methodologies, and training opportunities for antibody lab directors and personnel.
Dr. Jonathan Peat is the Business Development Manager of QuantuMDx, with years of experience in molecular biology and commercialization. He began his career in Glasgow whilst studying for his Ph.D. in Immuno-Genetics. After a number of years carrying out post-doctoral research in both Glasgow and Newcastle, Jonathan became part of CELS in the North East. As a Business Solutions Manager he helped biotechnology companies within the North East of England find funding, facilitated collaborations and gave export advice. He currently leads QuantuMDx’s Business Development and Marketing team, helping develop the forward facing aspect of the company and liaising with all partners and prospective business connections. Jonathan has a wealth of experience working in academic, research and commercial environments and managing business relationships.
Dr. Andrea J. Pruijssers is the Research Assistant Professor of Pediatrics at the Vanderbilt Institute for Infection, Immunology and Inflammation. She earned a Masters of Science in Cell and Molecular Biology from Wageningen University in Wageningen, The Netherlands, and a Ph.D. in Entomology from the University of Georgia in Athens, Georgia. She received postdoctoral training in the laboratory of Terence Dermody at Vanderbilt University Medical Center. At Vanderbilt, her research focuses on the development of antiviral therapies for emerging coronavirus (CoV) infections.